LDTs Around the World
Curious about how laboratory-developed tests are regulated in other countries? We compare in-house test guidance across six regions
Already a member? Log in here
3 Thoughts on the FDA’s Final LDTs Rule
Regulatory expert Julie Ballard shares her first thoughts on the final rule for lab-developed tests and immediate steps for labs
A Debate—Resolved: Immunohistochemistry Should Be Regulated As An Assay
Join G2 Intelligence for this interactive discussion about whether clinical immunohistochemistry testing should be a stain or an assay, with our experts offering arguments for and against the proposed changes